151 related articles for article (PubMed ID: 8323171)
1. Gonadotropin-releasing hormone agonist as a probe for the pathogenesis and diagnosis of ovarian hyperandrogenism.
Rosenfield RL; Ehrmann DA; Barnes RB; Sheikh Z
Ann N Y Acad Sci; 1993 May; 687():162-81. PubMed ID: 8323171
[TBL] [Abstract][Full Text] [Related]
2. Studies of the nature of 17-hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism.
Rosenfield RL; Barnes RB; Ehrmann DA
J Clin Endocrinol Metab; 1994 Dec; 79(6):1686-92. PubMed ID: 7989476
[TBL] [Abstract][Full Text] [Related]
3. Detection of functional ovarian hyperandrogenism in women with androgen excess.
Ehrmann DA; Rosenfield RL; Barnes RB; Brigell DF; Sheikh Z
N Engl J Med; 1992 Jul; 327(3):157-62. PubMed ID: 1319000
[TBL] [Abstract][Full Text] [Related]
4. Source localization of androgen excess in adolescent girls.
Ibáñez L; Potau N; Zampolli M; Prat N; Gussinyé M; Saenger P; Vicens-Calvet E; Carrascosa A
J Clin Endocrinol Metab; 1994 Dec; 79(6):1778-84. PubMed ID: 7989484
[TBL] [Abstract][Full Text] [Related]
5. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome.
White D; Leigh A; Wilson C; Donaldson A; Franks S
Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565
[TBL] [Abstract][Full Text] [Related]
6. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome.
Barnes RB; Rosenfield RL; Burstein S; Ehrmann DA
N Engl J Med; 1989 Mar; 320(9):559-65. PubMed ID: 2521688
[TBL] [Abstract][Full Text] [Related]
7. Ovarian steroidogenic responses to gonadotropin-releasing hormone agonist testing with nafarelin in hirsute women with adrenal responses to adrenocorticotropin suggestive of 3 beta-hydroxy-delta 5-steroid dehydrogenase deficiency.
Barnes RB; Ehrmann DA; Brigell DF; Rosenfield RL
J Clin Endocrinol Metab; 1993 Feb; 76(2):450-5. PubMed ID: 8381802
[TBL] [Abstract][Full Text] [Related]
8. Modified dexamethasone and gonadotropin-releasing hormone agonist (Dx-GnRHa) test in the evaluation of androgen source(s) in hirsute women.
Bidzińska B; Tworowska U; Demissie M; Milewicz A
Przegl Lek; 2000; 57(7-8):393-6. PubMed ID: 11109312
[TBL] [Abstract][Full Text] [Related]
9. In-vivo ovarian androgen responses to recombinant FSH with and without recombinant LH in polycystic ovarian syndrome.
Cheung AP; Pride SM; Yuen BH; Sy L
Hum Reprod; 2002 Oct; 17(10):2540-7. PubMed ID: 12351525
[TBL] [Abstract][Full Text] [Related]
10. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women.
Barnes RB; Rosenfield RL; Ehrmann DA; Cara JF; Cuttler L; Levitsky LL; Rosenthal IM
J Clin Endocrinol Metab; 1994 Nov; 79(5):1328-33. PubMed ID: 7962325
[TBL] [Abstract][Full Text] [Related]
11. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
Ibañez L; Hall JE; Potau N; Carrascosa A; Prat N; Taylor AE
J Clin Endocrinol Metab; 1996 Nov; 81(11):4103-7. PubMed ID: 8923867
[TBL] [Abstract][Full Text] [Related]
12. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
[TBL] [Abstract][Full Text] [Related]
13. Polycystic ovary syndrome.
Goudas VT; Dumesic DA
Endocrinol Metab Clin North Am; 1997 Dec; 26(4):893-912. PubMed ID: 9429864
[TBL] [Abstract][Full Text] [Related]
14. An attempt to alter the pathophysiology of polycystic ovary syndrome using a gonadotrophin hormone releasing hormone agonist--Nafarelin.
Williams IA; Shaw RW; Burford G
Clin Endocrinol (Oxf); 1989 Sep; 31(3):345-53. PubMed ID: 2533526
[TBL] [Abstract][Full Text] [Related]
15. Ovarian and adrenal function in polycystic ovary syndrome.
Rosenfield RL
Endocrinol Metab Clin North Am; 1999 Jun; 28(2):265-93. PubMed ID: 10352919
[TBL] [Abstract][Full Text] [Related]
16. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.
Nestler JE; Jakubowicz DJ
N Engl J Med; 1996 Aug; 335(9):617-23. PubMed ID: 8687515
[TBL] [Abstract][Full Text] [Related]
17. Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome.
Gonzalez F; Hatala DA; Speroff L
Am J Obstet Gynecol; 1991 Sep; 165(3):535-45. PubMed ID: 1832519
[TBL] [Abstract][Full Text] [Related]
18. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing.
Chang PL; Lindheim SR; Lowre C; Ferin M; Gonzalez F; Berglund L; Carmina E; Sauer MV; Lobo RA
J Clin Endocrinol Metab; 2000 Mar; 85(3):995-1000. PubMed ID: 10720029
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
Gambineri A; Patton L; De Iasio R; Palladoro F; Pagotto U; Pasquali R
J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
[TBL] [Abstract][Full Text] [Related]
20. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens.
Nestler JE; Jakubowicz DJ
J Clin Endocrinol Metab; 1997 Dec; 82(12):4075-9. PubMed ID: 9398716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]